硫唑嘌呤,临床注释-2,变异和临床注释数据

硫唑嘌呤

临床注释ID

1451237240

药物名称(英)

azathioprine

变异单倍型

TPMT*1, TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C, TPMT*6

基因

TPMT

证据级别

水平覆盖

水平修饰符

Tier 1 VIP

表现型类别(英)

Toxicity

表现型类别

毒性

分数

118.75

PMID计数

计数的证据

表现型

白细胞减少症；骨髓抑制

表现型(英)

Leukopenia;Myelosuppression

最新日期

2022/4/13 0:00:00

URL

https://www.pharmgkb.org/clinicalAnnotation/1451237240

专业人口(英)

Pediatric

专业人口

儿科

临床等位基因

id	等位基因	注释文本
1128	*6	The TPMT6 allele has been assigned as a no function allele by the DPWG. Patients carrying the 6 allele in combination with a normal or a no function allele may have decreased likelihood of experiencing toxicity when treated with azathioprine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Note that this allele has been assigned as an uncertain function allele by CPIC. Other genetic and clinical factors may also influence azathioprine toxicity.
1127	*3C	The TPMT3C allele has been assigned as a no function allele by CPIC. Patients carrying the 3C allele in combination with a normal or a no function allele may have decreased likelihood of experiencing toxicity when treated with azathioprine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence azathioprine toxicity.
1126	*3B	The TPMT3B allele has been assigned as a no function allele by CPIC. Patients carrying the 3B allele in combination with a normal or a no function allele may have decreased likelihood of experiencing toxicity when treated with azathioprine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence azathioprine toxicity.
1125	*3A	The TPMT3A allele has been assigned as a no function allele by CPIC. Patients carrying the 3A allele in combination with a normal or a no function allele may have decreased likelihood of experiencing toxicity when treated with azathioprine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence azathioprine toxicity.
1124	*2	The TPMT2 allele has been assigned as a no function allele by CPIC. Patients carrying the 2 allele in combination with a normal or a no function allele may have decreased likelihood of experiencing toxicity when treated with azathioprine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence azathioprine toxicity.
1123	*1	The TPMT1 allele has been assigned as a normal function allele by CPIC. Patients carrying the 1 allele in combination with another normal function allele may have decreased likelihood of experiencing toxicity when treated with azathioprine as compared to patients with two no function alleles or a no function allele in combination with a normal function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence azathioprine toxicity.

临床证据

id	证据的ID	总结
256	1184174686	TPMT 1/3A + 3A/3A is not associated with risk of Gastrointestinal side effects when treated with azathioprine in people with Inflammatory Bowel Diseases as compared to TPMT 1/1.
255	1449161632	TPMT 3C is not associated with Drug Toxicity when treated with azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases as compared to TPMT 1.
254	1449161615	TPMT 6 is not associated with Drug Toxicity when treated with azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases as compared to TPMT 1.
253	1448268960	TPMT 3A + 3B + 3C is associated with increased likelihood of Myelosuppression when treated with azathioprine in people with Inflammatory Bowel Diseases as compared to TPMT 1/*1.
252	1448268166	TPMT 3A + 3C is associated with increased likelihood of Leukopenia and Neutropenia when treated with azathioprine or mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT 1/1.
251	1448261284	TPMT 1/3C is not associated with risk of Leukopenia when treated with azathioprine or mercaptopurine in people with Crohn Disease as compared to TPMT 1/1.
250	1447983088	TPMT 1/3C is associated with increased risk of Leukopenia when treated with azathioprine in people with Inflammatory Bowel Diseases as compared to TPMT 1/1.
249	1447682889	TPMT 1/3C is associated with Leukopenia when treated with azathioprine in children with Crohn Disease.
248	1184467185	TPMT 1/3A + 1/3C + 3A/3A is associated with increased risk of Leukopenia when treated with azathioprine in people with Inflammatory Bowel Diseases as compared to TPMT 1/1.
247	1184407209	TPMT 1/3A + 1/3C is not associated with increased likelihood of myelosuppression or any other side effect when treated with azathioprine in people with Inflammatory Bowel Diseases as compared to TPMT 1/1.
246	1184349431	TPMT 1/3A + 3A/3A + 1/3C + 3C/3C is associated with increased likelihood of Bone Marrow toxicity when treated with azathioprine, mercaptopurine or purine analogues in people with Inflammatory Bowel Diseases as compared to TPMT 1/1.
245	1184349305	TPMT 1/3A + 1/3B + 1/3C is associated with decreased hematological indices when treated with azathioprine in people with Kidney Transplantation as compared to TPMT 1/1.
244	1184349269	TPMT 1/3A + 1/3C is associated with decreased leukocytes and neutrophils when treated with azathioprine in people with heart transplantation as compared to TPMT 1/1.
243	1184348908	TPMT 3A/3A is associated with severe myelosuppression when treated with azathioprine in people with Kidney Transplantation.
242	1184348490	TPMT 1/3C is associated with increased likelihood of haematopoietic toxicity when treated with azathioprine in people with Kidney Transplantation.
241	1184272572	TPMT 1/3C is not associated with risk of hematotoxicity or hepatotoxicity when treated with azathioprine in people with Kidney Transplantation as compared to TPMT 1/1.
240	1184233799	TPMT 1/3C is not associated with myelosuppression when treated with azathioprine in people with Inflammatory Bowel Diseases as compared to TPMT 1/1.
239	1184233780	TPMT 3C/3C is associated with increased risk of severe myelosuppression when treated with azathioprine in people with Hepatitis, Autoimmune as compared to TPMT 1/1.
238	1184233750	TPMT 1/3C + 1/6 is not associated with likelihood of adverse events when treated with azathioprine in people with Lupus Erythematosus, Systemic as compared to TPMT 1/1.
237	1184233729	TPMT 1/3C is associated with increased risk of leukopenia when treated with azathioprine, mercaptopurine or purine analogues in people with Inflammatory Bowel Diseases as compared to TPMT 1/1.
236	1184233570	TPMT 1/3C is not associated with increased likelihood of severe adverse reactions when treated with azathioprine in people with Inflammatory Bowel Diseases as compared to TPMT 1/1.
235	1184233545	TPMT 1/3C is associated with increased likelihood of myelosuppression when treated with azathioprine in people with Kidney Transplantation as compared to TPMT 1/1.
234	1184233329	TPMT 3A/3C is associated with severity of leukopenia when treated with azathioprine, cyclosporine and prednisone in people with Kidney Transplantation.
233	1184233233	TPMT 1/2 + 1/3A + 1/3C is associated with increased likelihood of leukopenia when treated with azathioprine, cyclosporine and prednisone in people with Kidney Transplantation as compared to TPMT 1/1.
232	1184175442	TPMT 1/3A + 1/3C is not associated with likelihood of Leukopenia, malaise and Pancreatitis when treated with azathioprine in children with Inflammatory Bowel Diseases as compared to TPMT 1/1.
231	1184174715	TPMT 3A/3A is associated with increased severity of myelosuppression when treated with azathioprine in people with Inflammatory Bowel Diseases.
230	1184174663	TPMT 3A/3A is associated with increased severity of bone marrow supression when treated with azathioprine in people with Colitis, Ulcerative.
229	1184173900	TPMT 1/3A is associated with increased risk of low leukocyte counts when treated with azathioprine in people with Rheumatic Diseases as compared to TPMT 1/1.
228	1184136197	TPMT 1/3A + 1/3C is associated with increased likelihood of haematological toxicity or hepatotoxicity when treated with azathioprine in people with neurological problems as compared to TPMT 1/1.
227	1184134311	TPMT 1/3A is associated with hepatic toxicity when treated with azathioprine, mercaptopurine or purine analogues in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.
226	1184134111	TPMT 1/2 + 1/3A is not associated with likelihood of adverse events when treated with azathioprine, mercaptopurine or purine analogues in children with Inflammatory Bowel Diseases as compared to TPMT 1/1.
225	1184133979	TPMT 2 + 3A + 3B + 3C is not associated with likelihood of adverse events when treated with azathioprine, mercaptopurine or purine analogues in children with Inflammatory Bowel Diseases as compared to TPMT *1.
224	1449750678	Genotype CT is not associated with increased likelihood of Leukopenia when treated with azathioprine in people with Autoimmune Diseases, Lupus Erythematosus, Systemic and Sjogren's Syndrome as compared to genotype TT.
223	1451237464	Allele C is not associated with increased likelihood of Leukopenia when treated with azathioprine in people with Hepatitis, Autoimmune as compared to allele T.
222	1448266607	TPMT poor metabolizers are associated with increased likelihood of Leukopenia and Myelosuppression when treated with azathioprine in people with Inflammatory Bowel Diseases as compared to genotype 1/1.
221	1184414133	TPMT intermediate metabolizer phenotype is associated with increased likelihood of intolerable side effects when treated with azathioprine in people with Inflammatory Bowel Diseases as compared to TPMT normal metabolizer phenotype.
220	1184407184	TPMT intermediate metabolizers is associated with increased likelihood of adverse events when treated with azathioprine, mercaptopurine or purine analogues in people with Inflammatory Bowel Diseases as compared to TPMT 1/1.
219	1184349913	TPMT intermediate metabolizer genotype is associated with increased likelihood of adverse effects when treated with azathioprine in people with Inflammatory Bowel Diseases as compared to TPMT 1/1.
218	1184233739	TPMT intermediate metabolizer phenotype is associated with decreased risk of leukopenia when treated with azathioprine, mercaptopurine or purine analogues in people with Inflammatory Bowel Diseases as compared to TPMT poor metabolizer phenotype.
217	1184174068	TPMT intermediate metabolizer phenotype is associated with increased risk of mild leukopenia when treated with azathioprine, mercaptopurine or purine analogues as compared to TPMT normal metabolizer phenotype.
216	1184174063	TPMT poor metabolizer phenotype is associated with increased risk of myelotoxicity when treated with azathioprine, mercaptopurine or purine analogues as compared to TPMT normal metabolizer phenotype.
215	PA166104933	Annotation of CPIC Guideline for azathioprine and NUDT15, TPMT

临床病史

id	类型	评论
1618	Update	Added PMIDs 16396707, 20175817, 16202677, 10376773, 12172211, 19682195, 18616518, 16543290, 12269967 to evidence, added phenotype description for *6, updated other phenotype descriptions.
1617	Update	CA score added as part of scoring system release. LOE assigned following curator review.
1616	Update	Added gene name to text
1615	Update	Attached CPIC guideline and removed override. Added conflicting evidence statement.
1614	Update	Changed decreased function to no function
1613	Create	Created

最新招商产品更多>>